Gh Research Plc Stock Today
| GHRS Stock | USD 9.69 0.26 2.76% |
Performance6 of 100
| Odds Of DistressLess than 45
|
GH Research is selling for under 9.69 as of the 30th of January 2025; that is 2.76 percent increase since the beginning of the trading day. The stock's lowest day price was 9.33. GH Research has 45 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. The performance scores are derived for the period starting the 31st of December 2024 and ending today, the 30th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of June 2021 | Category Healthcare | Classification Health Care |
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland. Gh Research is traded on NASDAQ Exchange in the United States.. The company has 52.03 M outstanding shares of which 2.41 M shares are currently shorted by private and institutional investors with about 30.57 trading days to cover. More on GH Research PLC
Moving against GHRS Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
GHRS Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGH Research can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand GH Research's financial leverage. It provides some insight into what part of GH Research's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
GH Research PLC (GHRS) is traded on NASDAQ Exchange in USA. It is located in Joshua Dawson House, Dublin, Ireland, D02 RY95 and employs 49 people. GH Research is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 490.62 M. GH Research PLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 52.03 M outstanding shares of which 2.41 M shares are currently shorted by private and institutional investors with about 30.57 trading days to cover.
GH Research PLC currently holds about 265.38 M in cash with (33.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.1.
Check GH Research Probability Of Bankruptcy
Ownership AllocationGH Research PLC secures a total of 52.03 Million outstanding shares. Over half of GH Research's outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check GHRS Ownership Details
GHRS Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Blackrock Inc | 2024-09-30 | 64.9 K | |
| Laurion Capital Management Lp | 2024-09-30 | 48.4 K | |
| Alps Advisors Inc | 2024-09-30 | 38.4 K | |
| Woodline Partners Lp | 2024-09-30 | 37.2 K | |
| Northern Trust Corp | 2024-09-30 | 32.2 K | |
| Advisorshares Investments, Llc | 2024-09-30 | 31.2 K | |
| Renaissance Technologies Corp | 2024-09-30 | 30.4 K | |
| Bank Of America Corp | 2024-09-30 | 28.1 K | |
| Barclays Plc | 2024-09-30 | 6 K | |
| Bvf Inc | 2024-09-30 | 10.4 M | |
| Ra Capital Management, Llc | 2024-09-30 | 6.7 M |
GH Research Historical Income Statement
GHRS Stock Against Markets
GH Research Corporate Management
| Naoise Gaffney | VP Property | Profile | |
| Julie ACA | VP Fin | Profile | |
| Magnus Halle | CoFounder Ireland | Profile | |
| Velichka MD | Chief Officer | Profile | |
| Florian M | CoFounder Chairman | Profile | |
| Theis MD | CoFounder CEO | Profile | |
| Aaron MBA | Chief Officer | Profile |
Additional Tools for GHRS Stock Analysis
When running GH Research's price analysis, check to measure GH Research's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GH Research is operating at the current time. Most of GH Research's value examination focuses on studying past and present price action to predict the probability of GH Research's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GH Research's price. Additionally, you may evaluate how the addition of GH Research to your portfolios can decrease your overall portfolio volatility.